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Summary
Contemporary thoracic and cardiovascular surgery uses extensive equipment and devices to enable its performance. As the specialties develop
and new frontiers are crossed, the technology needs to advance in a parallel fashion. Strokes of genius or problem-solving brain-storming may
generate great ideas, but the metamorphosis of an idea into a physical functioning tool requires a lot more than just a thinking process. A modern
surgical device is the end-point of a sophisticated, complicated and potentially treacherous route, which incorporates new skills and knowledge
acquisition. Processes including technology transfer, commercialisation, corporate and product development, intellectual property and
regulatory routes all play pivotal roles in this voyage. Many good ideas may fall by the wayside for a multitude of reasons as they may not
bemarketable or may be badly marketed. In this article, we attempt to illuminate the components required in the process of surgical innovation,
which we believe must remain in the remit of the modern-day thoracic and cardiovascular surgeon.
# 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
Keywords: Innovation; Intellectual property; Commerce; Industry; Technology transfer; Cardiac surgical procedures
www.elsevier.com/locate/ejcts
European Journal of Cardio-thoracic Surgery 37 (2010) 613—6251. Introduction
Thoracic and cardiovascular surgery has developed into
prevailing disciplines that use the best products that
contemporary technology can offer. Historically, operations
have been limited by the equipment availability of their era.
There was a limit to how much could be done with a scalpel
and a pair of forceps. Technological evolution and surgical
progress are therefore inextricably linked, with surgery being
the more dependent partner in the symbiotic relationship.
The expectations on today’s surgeons have intensified
exponentially. The contemporary era is especially challenging
in that it has to be transparent in the presence of amuchmore
unforgiving litigious atmosphere. The challenge is to deliver
unremitting excellence despite the constant delivery of
increasingly challenging surgical substrate, with the expecta-
tion of increased service delivery whilst honouring the need to
diminish risk [1]. Thoracic and cardiovascular surgeons
therefore should be prepared to embrace new technology§ We are grateful for support from the NIHR Biomedical Research Centre
Funding Scheme.
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benefit through the facilitation of health-care innovation [2].
Through this article,weattempt tobring to theattentionof
innovative surgeons andhealth-care professionals, the aspects
and factors we consider vital in turning good ideas into reality.
The main issues that we attempt to cover include pertinent
intellectual property (IP) and protection issues, financing
dilemmas, commercialisation, strategic plans for idea con-
version to product manufacture and regulatory routes. The
domains discussed are complex and this article intends to
deliver only a simplified overview. We accept that much of the
information presented applies generically to all ‘medical
devices’,which includeall surgical devices.Where possiblewe
have filtered the information and attempted to restrict
descriptions to be specifically relevant to aspects of surgical
innovation.We have no expectations that inventiveminds will
take on future innovative development sole-handed but we
hope that this information will make them aware of and help
them to harness and use established resources.
2. Innovation: definitions, drivers and hold-ups
Innovation is a complex term, and it is important to
understand exactly what is inferred in its use. The
differences between discovery, invention and innovationSurgery. Published by Elsevier B.V. All rights reserved.
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Invention is the occurrence of the idea or de novo discovery of
a phenomenon, and discovery is the introduction of new
fields of practice [2—5]. Innovation follows and describes
research that contributes to an already existing field, the
attempt to carry it out in practice, the development of novel
practice or provision of an alternative solution through the
introduction of new elements to what is already established
[1—5]. The basic stages which constitute this process are
invention, innovation and commercialisation [2].
There are many reasons to justify surgeons’ endorsement
of this subject area [6]. Ideally, the purpose of innovation
should be to enable the introduction of contemporary
technology to advance clinical practice facilitating the
delivery of optimised health care to the population. It
should be the means by which an innovative person can
implement good ideas, designed to introduce improvements.
In reality, it is the interface with the world of finance and the
potential in this area that accounts for one of the strongest
drivers of innovation, not in terms of ‘why it should exist’ but
in terms of ‘why it does exist’. At an international level,
surgical and academic innovations generate massive rev-
enue. It is those ideas that generate currency, which attract
investment and are more likely to get developed. The
corollary is that ideas which do not generate currency are less
likely to get off the ground. Therefore, it would appear that
financial ramifications are the drivers of innovation. In this
way, financial drive can contribute to global health care and,
as a surrogate result, fulfils the ethical intention of
innovation. Without this inevitable financial association, it
could be argued that innovation would experience major
inertia issues and falter early, ultimately compromising
medical progress.
Aside from the improvement of health care and revenue
generation, which can be royalty income or increasing
institutional resources, the introduction of new devices
offers several other important opportunities, global
extension of a surgeon’s impact, intellectual stimulation,
academic promotion and the creation of an enduring
legacy [7].
Having established why innovation should and does exist,
the fact remains that its introduction is not always a smooth
operation. The professional environment is not necessarily
optimally setup to enable surgeons to get involved, especially
when they may be dealing with an imbalance of increased
workload and decreased reimbursement. Furthermore, a
counterweight to the enthusiasm for adopting novelty is the
justified tendency to avoid unnecessary risk, and this may
slow the unmitigated implementation of innovation [6]. We
aim to facilitate this process through the provision of
essential information to potential innovators.
3. Innovation, surgeons and ideas
It is worth considering two important issues: the
generation of the idea and who has it. It may be a
serendipitous stroke of genius, a ‘eureka’ moment or the
result of a systematic problem-solving approach. What is
certain is that surgeons are in the best position to have
creative views on surgery and also to spot the ‘emergingmarket’ [6]. They encounter unique observational experi-
ences in an environment conducive to innovation [1,4]. Other
factors recognised to contribute to the generation of good
ideas are the innovator’s personality, location, being in the
right place at the right time and the ability tomake decisions,
all of which hopefully are surgical attributes [4,6]. These
factors justify why surgeons should be involved in innovation.
We propose that surgeons should remain pivotal in the
process, and take responsibility in remaining contemporary
and study applied surgical innovation.
4. Discussion
4.1. What is a medical device?
According to the federal Food, Drug, and Cosmetic Act
(section 2001), a device is ‘an instrument, apparatus,
implement, machine, contrivance, implant, in vitro reagent,
or other similar article that is intended for use in the
diagnosis of disease or other conditions, or in the cure,
mitigation, treatment or prevention of disease [8]’. The term
covers a massive spectrum ranging from dressings to the
components of a fully kitted robotic operating suite and
incorporating everything in between. Much of the informa-
tion described in this article uses references pertaining to all
devices, but we have focussed as much as possible on
surgically relevant information.
4.2. Protection: intellectual property and multiple
layers of protection
A term introduced by the World Intellectual Property
Organization (WIPO) in the 1960s, IP is broadly defined as
‘creations of the human mind’ and is attached to its own
specific legal criteria (Table 1 — Link 1). It is crucial to
understand the ramifications of intellectual property rights
(IPRs) in the context of surgical innovation and device
development since no product can come to market without
these. IP is essentially formed by four categories, which may
be used in isolation or in combination: patents, trademarks,
copyrights and trade secrets — each contributing in different
ways to the final protection strategy with diverse IP
implications and end-points [9].
Prior to any exposure, a common theme to all IPs is the
question of disclosure. Timed disclosure and non-disclosure
prior to solid IP protection is paramount for success. In the
event of public disclosure, a 1-year grace period exists in the
United States to complete a patent application. No such
grace period exists in Europe [9]. Furthermore, award of a
patent does not make the owner of the IP immune from
infringements. On the contrary, patents are challenged, and
defending them is expensive, on average, costing $5.3million
United States Dollars (USD) [10].
4.2.1. Trademarks and trade names
Trademarks are defined as ‘combinations of words,
phrases, symbols or designs that identifies and distinguishes
the sources of the goods of one party from those of others’
[11]. The United Kingdom Intellectual Property Office
(UKIPO) describe the trademark as ‘. . .a sign which can
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Table 1
Useful links and web-based references.
1 World Intellectual Property Organisation (WIPO)
Understanding Intellectual Property:
World Intellectual Property Organisation. PDF
http://www.wipo.int/freepublications/en/intproperty/895/wipo_pub_895.pdf
2 United Kingdom Intellectual Property Office (UKIPO) http://www.ipo.gov.uk/
3 NHS Innovations for London http://www.nhsinnovationslondon.com/
4 Imperial Innovations http://www.imperialinnovations.co.uk/index.php
5 Department of Health http://www.dh.gov.uk/en/index.htm
6 Cabinet Office (on 3rd sector) http://www.cabinetoffice.gov.uk/the_third_sector.aspx
7 Imperial Innovations Distribution Policy http://www3.imperial.ac.uk/hr/procedures/support/intellectualpropertyrights
8 MHRA: Medicines & Medical Devices Regulation:
What you need to know. PDF
http://www.mhra.gov.uk/home/groups/commsic/documents/websiteresources/con2031677.pdf
9 Global Harmonisation Task Force (GHTF) http://ghtf.org/
10 Medicines and Healthcare Regulatory Agency (MHRA) http://www.mhra.gov.uk/home/groups/comms-/documents/websiteresources/con2031677.pdf
11 CE Marking http://www.cemarking.net/alura_xl_com/alura_xl_com_homepage.php
12 US Food and Drug Administration (FDA) http://www.fda.gov/cdrh/devadvice/overview.html
13 Quality & Regulatory Associates http://qrasupport.com/FDA_MED_DEVICE.html#fda_med_device
14 International Organisation for Standardisation (ISO) http://www.iso.org/iso/home.htm
15 Stanford Biodesign http://innovation.stanford.edu/bdn/index.jspdistinguish . . . goods and services from those of . . .
competitors’ (Table 1 — Link 2).
The presentation of the trademark is a key issue and is
specific to words, logos or their combination. This specificity
includes the colour, font, placement and all features of a logo
or ‘name, slogan, symbol or other indicum . . . to distinguish
the source . . .’ (Table 1 — Link 2) [9]. Other types of marks
exist (such as service marks, coined marks and arbitrary
marks), although these are less relevant to surgical
innovation.
To publicise that a claim is being made, trademarks are
represented by ‘TM’ (and services marked by ‘SM’). This can
occur without registering the mark. If a trademark is
registered, it receives the ‘W’ sign in addition. This confers
additional benefit in that it strengthens its IP claim [11]
(Table 1 — Link 2).
The trademark distinguishes the goods or service, that is,
helps the consumer to recognise a product. In addition,
trademarks alert the consumer as to the origin of the product
in terms of which company or enterprise produces it.
Trademarks also deliver a ‘guarantee function’ in that
recognition of a mark may be associated with an impression
of reputation, almost like a seal of approval. Finally, the
trademark contributes significantly to the product promo-
tion, in terms of its ‘appeal function’ to the consumer
(Table 1 — Link 1). If the trademark is represented, it must be
done so in exactly the same manner as that specified by the
owner [11].
Trademarks are not automatically ubiquitous. To obtain
cover in more than one territory, it is possible to apply for a
European community trademark with OHIM (the Office for
Harmonisation in the Internal Market (Trade Marks and
Designs)) or register through a treaty, for example, the
Madrid treaty [11] (Table 1 — Link 2).
In conclusion, advantages of trademarks include establish-
ment of ownership and facilitation of national exclusivity.
They add strength to the legal protection and may enable
future licensing agreements [11].
4.2.2. Copyrights
Copyright protects ‘work’ which is ‘fixed in a ‘tangible
form’ (NHS Innovations for London) (Table 1—Link 3). The ideaitself is not protected by copyright, but the description is. It is
therefore not as relevant in the IP protection issues ofmedical
devices and biotechnology [11]. An official registration system
is not required inmostpartsof theworld, including theUK.The
copyright is designated by the symbol# and thismaybeadded
to the product without any external regulation (Table 1 — Link
2). The protection that copyright affords is from the time of
creation until 70 years after the death of the creator [11].
Alternativemethods of proof of ownershipmay be to self-send
a sealed envelope containing the description and not opening
it on receipt (Table 1 — Link 2).
4.2.3. Trade secrets
Also known as ‘know how’, the trade secret describes the
‘grey area’ between the formal documented ingredients and
the final dish. It is the art or way of doing things [11]. If IPRs
were compared to cookery, the patents, trademarks and
copyrights would relate to the utensils and recipe, but the
trade secret or ‘know how’ would relate to how exactly the
chef puts all those factors together to end up with the pie´ce
de re´sistance. This is an area of interest because this
knowledge can make or break the final product. With it,
reproduction of the product becomes possible, without
which, the souffle´ may flop. Whereas the other forms of IP are
documented rigidly and protected in specific fashions, ‘know
how’ is not. It is something that may never be declared, and
never formally protected but provides a tier of IP that is
essentially free and enduring. The recipe for Coca-Cola is
probably the best-known example of this. Like any form of IP,
‘know how’ can be bought, sold or licensed (Table 1 — Link 3).
We have now described several tiers of potential IP. Their
instruction and maintenance is complex and should remain in
the realms of patent experts. Cullem describes five key tips
to successful IP development. These are to think synergis-
tically, to get professional IP advice early, to appreciate IP
leverage potential beyond patents, to do the right deals and
to align the efforts [12].
4.3. Translational research and commercialisation
Surgeons become an important but single part of a multi-
faceted system and certainly cannot convert an idea into a
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are required for different aspects of the development such as
engineers, scientists and lawyers, to name a few of them.
This process necessitates ‘translational research’.
Three types of research are described: basic, clinical and
translational. Basic refers to laboratory; clinical to that
involving human subjects; and translational bringing bench
innovations to the bedside. This classification is with the
proviso that there may be significant overlap among these
distinctions [5]. Further described as the process where
‘biologic concepts are expanded to clinical applications’,
translational research relies on this collaborative under-
standing between the surgeon, the industry and academic
institutions [1].
The importance of a healthy collaborative atmosphere is
indispensable. There are not many places where this group
effort occurs as part of a systematic organised protocol. An
example of where this does work is the established
collaborative system of surgical innovation at the Stanford
BioDesign Program [13].
Beyond this collaboration, successful translational
research also requires at least a degree of commercialisa-
tion. Research and product development are costly and
commercialisation provides for this. Commercialisation
may comprise close collaboration with the financial side
of the industry or the surgeons themselves becoming
more ‘entrepreneurial’ [9]. Generally, the ideas come from
the surgeon/scientist, but the realisation comes from the
industry.
Academia and commercialisation are not natural part-
ners. This inherent conflict must be addressed and resolved
to enable successful commercialisation. Traditionally con-
sidered a taboo area for clinicians, its avoidance is unrealistic
since exclusion of financial reality would soon flaw any health
system. This union remains a controversial ethical area and
invites multiple conflict of interest quandaries.
In considering commercialisation, it is perhaps the end-
point that reveals its purpose. Whereas academic success is
the fulfilment of its objective, the discovery of knowledge,
commercial success is measured by the quantity of revenue it
generates. The objective of technological development is
commercialisation in comparison with academic research,
which seeks to publish [13].
Riskin et al. add to these concepts by describing the
varied impact of differing technological developments on
the commercial world. They describe ‘disruptive’ versus
‘sustaining’ technology changes. Disruptive technology
‘topples industry leaders’ while sustaining technology
refers to the changes necessary to remain competitive.
A cardiac example of a disruptive technology change was
the introduction and consequent impact of percutaneous
treatment options on traditional surgical re-vascularisa-
tion. The sustaining technology component is illustrated by
the introduction of stents to follow through percutaneous
coronary angioplasty (PTCA) and keep PTCA active. This
classification exists as a result of the varied impact on
the market share [6]. Commercialisation is therefore
entwined with financial factors and cannot proceed
without developed IP [14]. The final steps of commercia-
lisation are completed by successful corporate and product
development.4.4. Technology transfer and ownership
Technology transfer is the ‘process of moving the
intellectual capital of an institution . . . into the public sector
. . . for the financial benefit of investors (and) the academic
institution . . .’ [15]. This entails a transfer of knowledge from
the university to the industry, which covers a spectrum and
ranges from patents to ‘know how’, bearing in mind that the
university and industry have different outcome objectives
[11].
There are many examples of Technology Transfer Offices,
which exist to facilitate bridging of the gap between
academia and the industry. This enables provision of
expertise in all areas of device development [2], for
example, Imperial Innovations (Table 1 — Link 4).
Having described how the system should function, there
remain many good ideas which fail to flourish because of a
translation failure. Some say this is because of ‘failure to
understand the next step’ and others blame the (surgeon’s)
inexperience in corporate negotiations and lack of tools to
take things further [3,9]. Adopting a more commercial
approach facilitates some aspects of the process, but
translation is complex and there is ‘no such thing as a
simple recipe’ [3].
4.5. Finance and funding
4.5.1. Global economic impact of innovation
Surgical innovation and equipment development are
inseparable from the world of finance. Though justifiably
expensive to cover development costs, innovation is capable
of generating serious revenue. The enormity of the global
economical impact of health innovation is illustrated by the
growth seen in the biotech sector.
In the United Kingdom, the government has allocated £207
million pounds sterling for the National Health Service (NHS)
Transitional Research and Development (R&D) for 2008—2009
with individual institutions such as the Imperial College
receiving allocations of £26 million pounds sterling (Depart-
ment of Health) (Table 1 — Link 5).
The European Biotech sector alone has tripled in the last
10 years and innovation remains an important economical
priority. In Europe, initiatives and strategies have been
introduced to facilitate innovational development, for
example, the European Union Life Science and Biotechnology
strategy launched at the Lisbon summit in 2002 [16].
In the United States, by the late 1990s, the US Food and
Drug Administration (FDA) had approved 500 000 medical
devices produced by around 23 000 different manufac-
turers. According to a report published in 1997, the
Massachusetts Institute of Technology (MIT) alone gener-
ated 4000 companies, which employed 1.1 million employ-
ees, amounting to a net of $232 billion USD [2,8]. In 2004,
American universities and institutes raised more than
$1.39 billion USD and applied for over 10 000 patents [7].
By 2005, the top 10 United States research hospitals
received $1.2 billion USD for innovation. It seems that the
Bayh-Dole created an expectation in terms of innovation,
and the amount of money invested in the industry supports
the notion that surgical innovation is essential to surgical
progress and remains actively encouraged [2].
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A significant difference is noted in the financial ramifica-
tions of devices and drugs. Whereas the development of a
drug costs $800million to $1 billion USD and usually generates
$1—3 billion USD, devices usually cost around $60 million USD
and generate annual revenue streams of the order of $50
million USD [17]. The price largely depends on the device in
question. ‘Start-up’ costs to bring devices to market range
from about $10 million USD for simple devices (Smart
CanulaTM) to $100 million USD for more complicated devices
(transcatheter heart valve). The most complex devices
(artificial hearts) cost even more [18—20].
In addition to direct commercial value, innovative
research also provides indirect institutional value. This
may be in terms of enhancement of reputation, prestige and
competitiveness. Inflation of such indirect institutional value
itself may lead to potential private philanthropy, and this, in
turn, may increase the direct commercial value [5].
4.5.3. If to invest, when to invest: entrance and exit
strategies
When investing, the baseline common denominator
influencing this decision is to address the balance between
the value of the idea versus the cost tomarket it. This is in the
context of remembering that good science does not
necessarily imply good business but good business does
attract investment [3,17]. In calculating the value of the
idea, the concept that this is not static but varies according
to its stage in its development process must be remembered.
Evaluation is multi-factorial, and several factors must be
considered incorporating a supply—demand analysis. In
considering this balance, there are three key factors. First,
it is important to consider the ‘technology’ addressing the
problem the technology can solve and whether it is
protectable; second, ‘market’ considerations, which include
an assessment of the demand and the competition; and third,
the ‘economic’ balance incorporating deliberation on cost
versus time taken to develop/see returns [17].
The decision of when to invest is influenced by a dynamic
inter-relationship between three incentivised parties: the
surgeon (inventor), the company and the investor. (There are
circumstances where the company self-invests.) From the
inventor’s perspective, funds are required to develop the
project inclusive of all factors, such as IPR and prototypes. If
a company is created or recruited to manage the project, it is
of paramount importance to match the capitalisation stage
to the company life cycle [21].
Entrance and exit strategies for investment need to be
considered from industrial and inventor’s perspectives. It is
prudent for these purposes to consider industrial recruitment
and investment together.
From the industrial perspective, the best investment
policy is to invest, as far as possible, in an entity when it is at
its cheapest, without compromising the chances of acquiring
it. Stoddard and Danielsen state that the further down the
development pathway the idea is, the higher the value. They
recommend that the optimal time to invest is just prior to the
exponential increase in value, which generally occurs
between phase I and II clinical trials [15]. In addition to
acquiring more for less, other incentives for early industrial
inclusion are that earlier involvement strengthens theindustry/investor’s IP allotment/control and also feeds the
time—pressure constraints that drive the industry [2]. In
addition, investors generally prefer quick returns [5].
Early financial (or non-)industrial involvement must be
balanced against the inventor/university’s perspective. This
may be in order to reduce early disclosure risk and also to
generate higher returns on investment. In the same way that
an investor wants to become involved just prior to an
exponential increase in value, for the ‘seller’, the longer this
can be postponed, the more advantageous it is in terms of
potential revenue generation [2]. Another aspect is that one
type of innovation may be more attractive to one investor
than another. Fries refers to the ‘perceived’ value of a
patent, and we relate this to investment incentive where
‘beauty is in the eye of the beholder’ [11]. In summary, the
ideal position for an investor would be to invest in an
innovation they like, when the product is cheap, followed by
the establishment of a quick return. This must be balanced
against the ‘needs’ of the seller.
4.5.4. Funding sources
There are many potential funding sources and, where
possible, it is recommended to use multiple sources rather
than depending on a single source [1]. We have classified
potential funding sources into four main groups (although
some categories may qualify for cross-group entry). They are
commercial, educational, governmental and third-sector
sources (Fig. 1).
Commercial funds cover several categories. In the first
instance, an individual may use personal funds or bank loans,
although it is essential to set up ‘safety’ boundaries in this
case [10]. Entrepreneurial support may be recruited through
private equity. In general, mature companies are supported
in this way but ‘speculative promise’ is also welcomed in this
category [21].
Strategic investors include angel investors, venture
capitalists and the industry [1,3,9,10,14,21,22]. Often used
to ‘jump start’ clinical or corporate development, angel
investors often invest their own money and are usually
friends, relatives and/or entrepreneurs [3,9,21]. ‘Angels’
who usually invest up to $1 million USD (in this context) are
defined as having a net worth higher than $1 million USD with
an annual income of more than $200 000 USD for each of the
previous 2 years [9].
Larger, further developed projects may qualify for the next
tier of investment, the venture capitalists. Recruitment of
these investors is more taxing and is competitive [9]. Whereas
angel investors invest their own money, venture capitalists
invest other people’s funds [3]. Recruiting venture capital
usually implies that there will be some change in ‘ownership’
and a degree of loss of control during the process [3,10].
Funding projects valued at $5—10 million USD, venture
capitalists are expected to generate returns to their investors
within 3—7 years. Similarly to angel investors, they themselves
take equity [9,10]. They require rigid business plans and, like
angel investors, will have regimented exit strategies [9,10].
Financial support from the industry is another option
[1,22]. Sachs summarises from personal experience that
there are many advantages to industrial financial collabora-
tion, but he cautions that support can be withdrawn as
quickly as it is implemented and that, with such support,
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Fig. 1. Potential funding sources for surgical innovation.several conditions are involved, whichmay impede disclosure
or interfere with publication policies [22].
Government and government-endorsed research councils
are also potential serious financial contributors [1,3,9].
These may be an important financial source for ‘focussed
multi-disciplinary projects’ [1]. Examples include the
National Institutes of Health, National Institute for Health
Research, NHS R&D transitional funding allocations and the
Translational Research Council, federal government Small
Business Innovation Research and Small Business Technology
Transfer Research grants exemplified by projects, such as the
Internet, which have originated from federal government-
sponsored scientific research [3,9]. Government funding may
take time to implement; so for speedier requirements, there
may be more of an indication for venture capital input,
although this may be at the cost of earlier disclosure [9].
Educational financial sources include university and
institutional resources and surgical specialty foundations
[1]. Professional bodies may also provide internal funding,
such as the ‘Innovation Loan Program’ or ‘Discovery
Translational’ funds of the Mayo Clinic [15]. At Imperial
College, ‘Imperial Innovations’ provides investment to get
ideas going (Table 1 — Link 4).
The third sector is defined by non-governmental value-
driven organisations and include the cabinet office (Table 1 —
Link 6), charitable trusts, private foundations and all
philanthropic sources [1,14].
4.5.5. Generation of capital and licensing
Having discussed options of raising funds to support
innovation, we now discuss methods of generating capital.
Stoddard and Danielsen describe consulting, know how and
licensing agreements [15]. The compensation is usually paid
as a royalty, ranging from 1.5% to 8% with an industry average
of 3% of net sales [7]. An accepted royalty rate is 25% of the
expected pre-tax net profits, although royalty division varies
geographically and between trusts [11,23]. The distribution
policy also changes according to the cumulative net revenue
generated by an idea. For example, at Imperial College, the
inventor keeps 100% of the revenue up to a value of the first
£50 000 pounds sterling. This percentage progressively drops
as the net gain increases with the faculty and college takingincreasing shares. When the net value exceeds £500 000
pounds sterling, the inventor’s share decreases to 35%
(Table 1 — Link 7).
Licensing is governed by licensing agreements, and these
enable the process of ‘transfer of patent rights from licensor
to licensee’. Exact terms must be defined to enable the right
to make, use or sell products based on a patented invention.
The terms cover the exclusivity of rights, field of use and
territory. Furthermore, Fries describes specific financial
terms that should be included in licensing agreements. These
include technology transfer, access fees and up-front
payment, patent prosecution and maintenance fees, mile-
stone payments, royalties, sub-license fees, minimum annual
royalties, equity considerations and royalty anti-stacking
provision [11]. The licensee pays the patent owner, and the
different types of license relate to howmuch control is given.
The different types are exclusive, non-exclusive, sole and
partially exclusive [11]. Licensing therefore provides a good
alternative to the ‘start-up’ route since the recruited
company organises the commercialisation and forward on
the agreed division of royalties [9].
There are, therefore, many different types of investors
available, and it is important to select the right type of
investor for the right project at the right time.
4.6. From idea to manufacture: innovation models,
product and corporate development
The voyage which transforms an idea into a marketable
product necessitates the evolution of the device itself (i.e.,
product development) and of the individuals (and their
financial standing) developing it (i.e. corporate develop-
ment). These components form the two arms of all innovation
models. The key to successful corporate development and
existence is an organised strategy and robust business plan.
When considering innovation, Heller et al. propose a
model based on combining the concepts of Moore and
Verloop. This model has three phases: firstly, idea generation
and crystallisation, followed by the second phase that is
‘development and demonstration of proof of concept’. (This
is inclusive of financial consideration and collaborations.)
The final phase is ‘delivery of innovation to patient care’
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Fig. 2. Summary of product development pathways [7,10,24,25].[13]. Toner and Tompkins similarly describe ‘invention’,
leading to ‘innovation’ and finally ‘commercialisation’ [2].
The corporate and product development processes are
inextricably linked with extensive cross-over but, for the
purposes of this article, we describe the key elements of the
processes separately. Even though the innovation processes
are often represented as stepwise sequential steps, in
practice, multiple steps should be developed synchronously
to enable an overall acceptable product development
timeline.
4.6.1. Product development and translational research
Productdevelopmentdescribes theprocess thatbeginswith
an idea and culminateswith a (licensed), purchasable product.
Several product development pathwaymodels are described in
the international literature, which describe key elements. In
Fig. 2wehave summarised fundamental points, as describedby
Mehta, Gingles, Bonutti et al. and the World Health Organiza-
tion (WHO). Using these sources, we have identified common
themes enabling us to propose a simplified overview of the
device development pathway, and this is represented as shown
in the figure [7,10,24,25]. These steps are
1. Idea crystallisation
2. Addressing IP and related issues
3. Concept-to-object translation
4. Build and test device
5. Regulatory routes (pre-market, placing on market, post-
market)
6. Manufacture
7. Entering and staying in the marketplace
8. Up-scaling of production
9. Broadening applications
10. De-commissioning
The first stage in development of a device is the idea and
its generation. Once an idea is formed, it is important toclarify what type of innovation it will provide since this will
influence the choice of the development pathway. Riskin
et al. describe two types: enabling and incremental
technology. Enabling innovation supports development in a
field whereas incremental innovation leads to marginal
improvement of already available technology [6].
‘Addressing IP and related issues’ is the next ongoing
stage, which accompanies the device throughout its life.
These issues are addressed earlier and in the first part of this
series [23].
‘Concept-to-object translation’ and ‘building and testing’
the device entails the building of a prototype, which is ‘a first
or preliminary form from which other forms are developed or
copied’ [26]. There must be availability of materials and
techniques to validate and execute the idea and commu-
nication between the ‘philosopher and artisan’ is essential as
is the involvement of those who benefit from the idea through
the generation of economic value [2].
To build the prototype, the idea must be refined. Steps
include development of formal engineering drawings,
materials testing, creation of working product and draw-
ing/design approval by the appropriate regulatory route. The
prototype may be built by the inventor, the university and/or
specialised companies [10].
Regulation of the manufacture, which occurs before and
after market entry, is discussed below.
Manufacture involves specific issues, all of which are
regulated. These include aspects such as sterilisation,
packaging and labelling [10]. To standardise manufacturing
quality, international standards are available, for example,
the development of ‘Good Manufacturing Practice’ (GMP) by
the WHO [25].
4.6.2. Corporate development
Following security of disclosure, the first step in corporate
development is the decision whether to proceed or not. A
good idea, even one promoting patient benefit is not
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influence this balance [15]. Bonnutti et al. describe three
options available to the surgeon with a good idea. The idea
can be presented and surrendered to a medical device
company; the surgeon can develop their own IP; or can join a
patent licensing firm. They suggest that the last option is the
best [10].
Gingles et al. describe two possible routes, the entre-
preneurial and corporate partnership routes, and summarise
the key steps. For the entrepreneurial model, they describe
five steps:
1. Decide company type
2. Register company
3. Construct business plan
4. Raise capital
5. Recruit manager
They describe the following steps for the corporate
partnership model [7]:
1. Disclosure agreements
2. Consideration intellectual property
3. Inventor input
4. Development product development pathway
5. Compensation arrangements
Essentially, the key choice is between an entrepreneurial
route and some form of corporate partnership [7]. Each routeFig. 3. Dynamic interaction between Academichas its own advantages and disadvantages, the discussion of
which is beyond the scope of this introductory article.
Whichever route is taken, it is almost always necessary to
recruit ‘external help’ since this brings intellectual expertise
and money to the table [1].
Having decided upon the route, the inventor is then
presented with further decisions. These are: when to
recruit help and which exit strategy to adopt. In Fig. 3, we
have shown the device development trail centrally leading
from idea to manufacture. The academic institution role is
shown on the left. The idea may start in the institute or be
brought to it, and the extent of time that the institute
remains actively involved in the rearing and maintenance
of the device is variable. For this reason, the point of
academic ‘take off’ may vary along the pathway, as
represented by the two-way arrow. The presence of the
academic institute’s influence along the trail is in
synchrony with the industrial or corporate presence. This
is represented by the curved arrow on the right. The point
of corporate recruitment is also variable as is the exit
point. Again, this is represented by the two-way arrow
demonstrating the dynamic interaction between the
inventor, the academic institute and the industry or
corporate representative.
Another factor influencing the timing of recruiting of
external assistance is the current stage of the company. This
is especially the case when following the bio-entrepreneur-
ial route. It is also related to financial implications, whichInstitute and Corporate Representative.
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Fig. 4. Inventor’s exit strategy based on Bonutti et al. [10].are discussed separately in the section on financing and
funding. Gertler et al. describe four progressive company
stages. These are the start-up, early, expansion and later
stages. These stages relate directly to the company
development timeline, which commences with a conceptual
or development phase followed by technology optimisation
and pre-testing. This leads to clinical trials and product
launch [21].
We have established the need for externalisation;
however, a point in time arrives where disunion and
separation may be the appropriate next step. We now
consider exit strategies for the inventor and the industry. The
point of academic/inventor ‘hand off’ is variable, influenced
mostly by the innovation type. There is no ‘correct answer’
for the best time to disengage. Depending on the invention,
the best ‘hand off’ time may be between invention and
innovation [2]. Alternatively, it may be optimal to retain
another idea within the academic institute well into the
innovation phase, leaving only the ‘business execution’ to
the industry [2]. The point of academic take off does not
necessarily coincide with the point of industrial intake since
the two may often co-exist until one party takes over. On an
individual level, the inventor/institute has several exit
strategy options. Bonnutti et al. summarise six exit strategies
and we have represented these in Fig. 4. The options are to
become a company consultant, to sell the product or idea,
license a patent, take the product to market or make a public
offering [10].
4.7. Regulatory routes
Once a product development is in progress, risk must be
assessed since there are stringent regulations that have to be
met prior to the introduction and release of medical devices
into the market place and health-care environment.Regulatory routes are essentially the requirements
enforced by individual countries to permit the use of a
device in that country. Ultimately, approval from govern-
ment bodies must be sought, although internal institutional
review is often required prior to approaching the national
regulator [7]. These territorial-specific routes enable the
‘safe translation’ of innovative research [5,7]. Different
regions exercise distinct routes, although common princi-
ples exist.
Regulatory routes are specific to what is being marketed
and devices and drugs currently experience different degrees
of attention with drugs generally undergoing much more
stringent checks [8]. All drugs brought to market must
undergo clinical trials whereas this requirement is not
reflected in device development. Devices are tested in
laboratories and are checked for mechanical and/or
electrical safety (Table 1 — Link 8).
Regulatory routes are also specific to the different stages
of corporate development. The WHO summarises and
describes three stages where government regulation is
applied. The stages are pre-market, ‘placing on market’
and post-market surveillance/vigilance. The pre-market
stage controls the product and is the responsibility of the
manufacturer. Regulated aspects are the device attributes,
manufacturing systems and labelling or representation.
‘Placing on market’ refers to the sale by the vendor. The
regulatory routes here focus on establishment registration
and advertising. Finally, post-market surveillance monitors
the after-sale by the vendor or user and monitors the
product, assessing performance and identifying and alerting
problems [25].
There has been an effort to unify regulatory routes on an
international level, and this is illustrated by the worldwide
initiatives of organisations such as the WHO and the Global
Harmonization Task Force (GHTF). They have proposed a
universal Medical Device classification system ‘according to
their perceived hazards’, Global Medical Device Nomencla-
ture (GMDN) and promotion of a medical device regulatory
model [24] (Table 1 — Link 9).
In both the EU and United States, devices are classified
into three classes [25]. The device class represents the risk
presented to the patient and the level of regulatory control
required [8]. The higher the class, the greater is the potential
risk. We will use the United Kingdom as a European example
and the American regulatory systems to illustrate these
central themes (Fig. 5).
4.7.1. Europe, United Kingdom and CE marking
Since the introduction of the single market in 1992,
European countries follow equivalent litigation in this area.
The pre-market phase is enforced by a compliance label,
which is called a ‘CE’ mark. The Medicines and Healthcare
Regulatory Agency (MHRA) is the active regulatory depart-
ment of the Department of Health and plays several roles
(Table 1 — Link 8).
The pre-marketing role is through the ‘appointment and
auditing of notified bodies’, which are third-party accred-
itation bodies [27]. In addition, the MHRA monitors adverse
events and feeds back this information to the manufacturer.
The MHRA is powerful, being empowered to remove products
from the market, and plays an active role in education [27].
J.A. Vecht et al. / European Journal of Cardio-thoracic Surgery 37 (2010) 613—625622
Fig. 5. Regulatory routes: Europe and United States.The ‘placing on market’ phase is facilitated through
monitoring information on adverts, labels and product
information leaflets. (Counterfeit medical devices are also
controlled as are products that are not necessarily licensed as
medical devices). [Table 1 — Link 8]. The MHRA relies on
clinicians and manufacturers reporting to them to enable
post-market surveillance, and this is implemented through
the adverse incident reporting scheme. They may issue a
medical device alert or product alert and can enforce
changes in design and disseminated information. Cardiac
prosthetic heart valves and annuloplasty rings have been
taken off the market by the MHRA (Fig. 5; Table 1 — Link 10).
The CEmark is amark of compliance using the letters ‘CE’.
We found very useful online information at ‘CEmarking.net’
(Table 1 — Link 11). Here, Zuyderwijk gives an online synopsis
lecture from which we have derived the following summary.
The ‘CE mark’ should be referred to as ‘CE marking’ and it is
an abbreviation for European Conformity or ‘Conformite
Europe´enne’. Applied by the manufacturer, its presence
indicates European safety compliance and enables marketing
in specific territories [27]. It is applied by the manufacturer,
and without it, in general, a medical device cannot be
marketed in Europe (Table 1 — Link 8). These territories are
the EU, European Free Trade Association (EFTA) and
candidate EU members such as Croatia. (It is noted that
Switzerland has a mutual agreement other than CE marking
that is considered equivalent.) It is important to emphasise
that the mark is not representative of quality. CE marking is
obligatory for any product which falls under the remit of the
‘New Approach Directives’ of the EU. For the purposes of this
article and health-care-related appliances, the relevant
directives are: Medical Devices (93/42/EEC), Active Implan-
table Medical Devices (90/385/EEC) and In Vitro Diagnostics
(98/79/EEC). In the UK, for anything other than a very low-
risk device, the CE mark must be verified by an independentcertification body or ‘notified body’, and these are appointed
by the MHRA (Table 1 — Link 8).
Class I devices (excluding thosewithmeasuring function or
sterility requirements) do not require pre-market approval
but must follow basic safety requirements. Other class I, class
II and III devices must be submitted to the regulator with ‘a
declaration of conformity to the appropriate EC directives
and details of the conformity assignment assessment
procedure followed’. For higher-risk devices, the corre-
sponding EC certificates issued by a notified bodymust also be
submitted to the competent authority [25].
4.7.2. United States
In the United States, regulatory routes are enforced by the
US FDA (Table 1 — Link 12). Most of the relevant regulations
are found in ‘title 21 code of federal regulations (CFR) part
800 to part 1299’ [8]. This includes not only specific routes for
devices, but also different routes for different devices [17].
As in Europe, class I devices only require basic regulations (or
general controls) such as sterility and are exempt from pre-
market notification. All device classes are subject to general
controls [28]. Higher device classes require more stringent
regulation [3,8]. Class II or ‘medium-risk’ devices require
‘special controls’ inclusive of labelling requirements,
mandatory performance standards, post-market surveillance
and FDA guidance. Products are then essentially cleared by
one of two routes: pre-market approval (PMA) or through a
‘510k’ marketing clearance. The 510(k) demonstrates
‘substantial equivalence to a legally marketed predicate
device’ and may be necessary for class II devices [7,8,28].
The PMA entitles study of devices in humans and is generally
required for class III devices. There are some class III devices
covered with a 510(k) [7,8,28].
Feldman et al. state that themajority of device regulation
in the US occurs via the 510(k) route [8]. Following ‘the
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2002’, the FDA is entitled to charge for their regulatory work.
PMAs are very expensive (>$3million USD) whereas 510(k)
cost less ($10—15 000 USD) [7]. The 510(k) review is quicker
to complete (20—90 days) than the PMA clearance, which
takes twice as long (180 days) (Quality and Regulatory
Associates) (Table 1 — Link 13).
The ‘placing on market’ phase in the United States
requires an ‘establishment registration’ [25]. This applies to
the place where the device is manufactured and costs $1861
USD (Table 1 — Link 12).
4.7.3. Post-market surveillance/vigilance — common
routes
The third phase of post-market surveillance/vigilance also
incorporates adverse events reporting. In the 1980s, the FDA
was criticised for inadequate post-market assessment and, as
a result, the Congress introduced the ‘safe medical devices
act’ in 1990, which was amended in 1992 [28]. Common
themes and requirements demonstrate global post-market
surveillance compliance (as defined by GHTF). The five
components of a comprehensive post-market regulatory
component include problem reporting, implant registration,
distribution records, recall procedure and complaint hand-
ling [25]. The FDA lists other basic regulatory requirements
that manufacturers must comply with. These are Establish-
ment registration, Good Manufacturing Compliance (GMP),
Medical Device Listing, Investigational Device Exemption
(IDE) for clinical studies Quality System (QS) regulation,
Labelling requirements and Medical Device Reporting (MDR)
(Table 1 — Link 12).
Hence there are clear routes, which must be adhered to,
that ensure a proposed device is health and safety compliant.
Other sources of advice and guidance are available from the
International Organization for Standardization, which issues
risk management advice to manufacturers (ISO 14971:2000)
(Table 1 — Link 14).
4.8. Entering the market place
We have described the key components that constitute a
successful idea to product passage. Their implementation
requires a well-managed multi-faceted team. This is
dependent on selecting the right team and executing the
right business plan.
4.8.1. The team
The innovation journey is not one to make alone. Expert
advice is necessary for all aspects of development, perhaps
with the exception of those in which the inventor feels
proficient. Areas to be covered include IP advice,
corporate direction, manufacturing expertise, regulatory
proficiency and marketing know how [10]. Crucial elements
remain sensible disclosure policies and a positive colla-
borative team environment. Whether progressing your own
IP or synergising with a corporation, expertise provision
beyond the capability of the academic institution will
make the voyage more seamless [2]. Chitwood also points
out that this is a great opportunity for surgeons to learn
new skills, and advocates interdisciplinary and industrial
collaboration [1].4.8.2. The business plan
The business plan is the way in which the overall plan is
implemented, and its construction and explanation is beyond
the scope of this article.
4.8.3. Planning and strategy
Getting onto the market requires information dissemi-
nation and advertising. This lies within the scope of the
marketing team but good scientific analysis and justi-
fication will also naturally enhance use and ultimately
sales.
It is important to question whether a project can ever
really finish or if it remains in an ongoing active cycle. As time
progresses, ‘new’ challenges may impinge on the main-
tenance and market phase of the product, for example,
customer feedback, the availability of new materials and
technology, new regulations and new markets. The inventors
and their team should be prepared to adapt to the market in
which they exist and upgrade, adjust or de-commission as the
environment dictates.
4.9. Surgical innovation in real life: ethical
considerations in practice and training
Considering surgical innovation according to the four
prima facie principles of medical ethics (autonomy,
beneficence, non-maleficence and justice) enables the
construction of a logical framework and raises interesting
dilemmas [29]. There are two aspects: the impact of a
specific device on a patient/recipient and contemplation of
the more generalised philosophical implications of surgical
innovation implementation.
Autonomy is essential and, we assume, universally
respected. This applies specifically to the scenario of an
individual patient/recipient. Depending on the innovation in
mind, patients should be fully involved in the decision-
making process and where applicable, consent may be
required.
Beneficence on an individual patient level has obvious
benefits with the scope of improving both prognosis and
quality of life. We have extensively discussed the broader
beneficial implications of surgical innovation,which are very
positive. However, controversies arise when deliberating
issues of non-maleficence. On an individual patient basis,
there is the issue of possible complications resulting directly
from a new device or procedure. This introduces a potential
risk, which may have an impact on the mortality and/or
morbidity outcome. This must be carefully balanced against
the benefits in a considered argument. Thinking beyond the
implications affecting an individual patient, it is important
to consider the more generalised issues. An important
concern is the danger that those involved in innovative
development may not be impartial in their judgement. It is
inevitable that a conflict of interest is introduced since
clinically successful products may lead to personal and
institutional monetary gain. Furthermore, if an inventor has
personal equity in the product, one may become biased and
unobjective in their assessment and management [10].
There may be a concern that the enthusiasm of the inventor
or promoter clouds the perception of the actual results,
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Fig. 6. Overview of surgical innovation.which may, in turn, could prejudice the appropriateness of
developments.
Justice in this scenario is the ‘moral obligation to act on
the basis of fair adjudication between competing claims’
[29]. To assist, there exist clear institutional and govern-
mental policies to prevent and discourage likely conflicts of
interest. It is the responsibility of inventors to familiarise
themselves with their local and national liability. A specific
recommendation is that it is good practice for inventors to
use their own devices and not just develop it in the hope that
others will use it [7]. Regulatory routes on surgical innovation
are stringent, although some would argue that all innovation
should be even more tightly audited and monitored through
an independent process.
It is our opinion that surgical innovation is an essential
prerequisite to keeping thoracic and cardiovascular
surgery competitive. This is especially the case in thecontext of an appropriate global attitude of a need for
better results in the presence of less morbidity. This
atmosphere probably propels forward non-surgical treat-
ment options so surgical options need to remain attractive,
novel and contemporary, and this cannot occur in isolation
of innovation. It is essential that surgeons are familiar with
the processes and resources available to turn good ideas
into realities. The importance of surgical innovation is also
ratified by the recent incorporation of IP and innovation
training into the surgical curriculum. One of the best
international examples is Stanford University where a
Surgical and Biodesign programme has been developed
(Table 1 — Link 15).
5. Conclusion
We have attempted to provide an overview of the
processes involved in the development of a medical device.
We have demonstrated that beyond a ‘good idea’, there are
many factors that need to be considered. Bringing together
all these components to achieve a safe, marketable device
that generates revenue requires skill, knowledge and
assistance. Fig. 6 is a schematic representation of our
overview of surgical innovation. There is no simple ‘quick fix’
and as the great American inventor Thomas Alva Edison said,
‘Invention is one percent inspiration and ninety nine percent
perspiration’.
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